# A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)

> **NCT06783192** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 14 (actual)

## Conditions studied

- Human Immunodeficiency Virus (HIV)
- HIV Pre-Exposure Prophylaxis

## Interventions

- **DRUG:** MK-8527
- **DRUG:** LNG/EE

## Key facts

- **NCT ID:** NCT06783192
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-14
- **Primary completion:** 2023-10-11
- **Final completion:** 2023-10-11
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06783192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06783192, "A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06783192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*